Identification

Name
Tolmetin
Accession Number
DB00500  (APRD01268)
Type
Small Molecule
Groups
Approved
Description

A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. [PubChem]

Structure
Thumb
Synonyms
  • 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid
  • 1-Methyl-5-P-toluoylpyrrole-2-acetic acid
  • 5-(P-Toluoyl)-1-methylpyrrole-2-acetic acid
  • Tolmetin
  • Tolmetina
  • Tolmétine
  • Tolmetino
  • Tolmetinum
External IDs
McN 2559 / McN 2559-21-98
Product Ingredients
IngredientUNIICASInChI Key
Tolmetin sodiumWL259637KX64490-92-2QGUALMNFRILWRA-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tolectin 200 Tab 200mgTablet245 mgOralMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1976-12-312002-08-02Canada
Tolectin 400 Cap 400mgCapsule400 mgOralMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1980-12-312002-08-02Canada
Tolectin Tab 600mgTablet600 mgOralJanssen Pharmaceuticals1987-12-312006-02-27Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-tolmetin Capsules 400mgCapsule400 mgOralNovopharm Limited1994-12-312005-08-10Canada
Tolmetin SodiumTablet200 mg/1OralMutual Pharmaceutical2009-09-04Not applicableUs
Tolmetin SodiumCapsule400 mg/1OralMylan Pharmaceuticals1993-05-27Not applicableUs
Tolmetin SodiumTablet, film coated600 mg/1OralMylan Pharmaceuticals1994-08-30Not applicableUs
Tolmetin SodiumCapsule400 mg/1OralMutual Pharmaceutical2009-09-04Not applicableUs
Tolmetin SodiumTablet, film coated600 mg/1OralStat Rx USA2009-11-022018-02-08Us
Tolmetin SodiumCapsule400 mg/1OralTeva2012-07-262017-09-30Us00093 2075 01 nlmimage10 c326e187
International/Other Brands
Tolectin (Teva) / Tolectin DS (Teva)
Categories
UNII
D8K2JPN18B
CAS number
26171-23-3
Weight
Average: 257.2845
Monoisotopic: 257.105193351
Chemical Formula
C15H15NO3
InChI Key
UPSPUYADGBWSHF-UHFFFAOYSA-N
InChI
InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)
IUPAC Name
2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetic acid
SMILES
CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1

Pharmacology

Indication

For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, including the treatment of acute flares long-term management. Also for treatment of juvenile rheumatoid arthritis.

Structured Indications
Pharmacodynamics

Tolmetin is a nonsteroidal anti-inflammatory agent. Studies in animals have shown tolmetin to possess anti-inflammatory, analgesic and antipyretic activity. In the rat, tolmetin prevents the development of experimentally induced polyarthritis and also decreases established inflammation. In patients with either rheumatoid arthritis or osteaoarthritis, tolmetin is as effective as aspirin and indomethacin in controlling disease activity, but the frequency of the milder gastrointestinal adverse effects and tinnitus was less than in aspirin-treated patients, and the incidence of central nervous system adverse effects was less than in indomethacin-treated patients. In patients with juvenile rheumatoid arthritis, tolmetin is as effective as aspirin in controlling disease activity, with a similar incidence of adverse reactions. tolmetin has produced additional therapeutic benefit when added to a regimen of gold salts and, to a lesser extent, with corticosteroids. Tolmetin should not be used in conjunction with salicylates since greater benefit from the combination is not likely, but the potential for adverse reactions is increased.

Mechanism of action

The mode of action of tolmetin is not known. However, studies in laboratory animals and man have demonstrated that the anti-inflammatory action of tolmetin is not due to pituitary-adrenal stimulation. Tolmetin inhibits prostaglandin synthetase in vitro and lowers the plasma level of prostaglandin E in man. This reduction in prostaglandin synthesis may be responsible for the anti-inflammatory action. Tolmetin does not appear to alter the course of the underlying disease in man.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UProstaglandin G/H synthase 1
inhibitor
Human
Absorption

Rapidly and almost completely absorbed with peak plasma levels being reached within 30-60 minutes after an oral therapeutic dose.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Essentially all of the administered dose is recovered in the urine in 24 hours either as an inactive oxidative metabolite or as conjugates of tolmetin.

Route of elimination
Not Available
Half life

Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.

Clearance
Not Available
Toxicity

Symptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Tolmetin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Tolmetin is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tolmetin is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Tolmetin is combined with 5-androstenedione.Experimental, Illicit
AbciximabTolmetin may increase the anticoagulant activities of Abciximab.Approved
AcebutololTolmetin may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolTolmetin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinTolmetin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tolmetin.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Aldosterone.Experimental, Investigational
AldoxorubicinTolmetin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Alendronic acid.Approved
AliskirenTolmetin may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Alminoprofen.Experimental
AlprenololTolmetin may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tolmetin.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Amcinonide.Approved
AmikacinTolmetin may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideTolmetin may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinTolmetin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodTolmetin may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Tolmetin is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Tolmetin is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Anisodamine.Investigational
AnnamycinTolmetin may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Antipyrine.Approved, Investigational
Antithrombin III humanTolmetin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanTolmetin may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Tolmetin is combined with Apocynin.Investigational
ApramycinTolmetin may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Tolmetin is combined with Apremilast.Approved, Investigational
ArbekacinTolmetin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinTolmetin may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTolmetin may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTolmetin may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Atamestane.Investigational
AtenololTolmetin may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azelastine.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tolmetin.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tolmetin.Investigational
BalsalazideTolmetin may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminTolmetin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTolmetin may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinTolmetin may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tolmetin.Approved
BenorilateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tolmetin.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Betamethasone.Approved, Vet Approved
BetaxololTolmetin may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Tolmetin.Approved, Investigational
BevantololTolmetin may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Tolmetin is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tolmetin.Approved, Investigational
BisoprololTolmetin may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTolmetin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTolmetin may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tolmetin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Bucillamine.Investigational
BucindololTolmetin may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Bufexamac.Approved, Experimental
BufuralolTolmetin may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tolmetin.Approved
BupranololTolmetin may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolmetin.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tolmetin.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Tolmetin is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tolmetin.Approved
CarprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololTolmetin may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolTolmetin may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Celecoxib.Approved, Investigational
CeliprololTolmetin may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinTolmetin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolmetin.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tolmetin.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Cilazapril.Approved
CinoxacinTolmetin may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidTolmetin may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tolmetin.Vet Approved
CloranololTolmetin may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Tolmetin is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tolmetin.Experimental
CyclosporineTolmetin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateTolmetin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTolmetin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTolmetin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanTolmetin may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinTolmetin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Tolmetin is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Tolmetin is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Delapril.Experimental
DesirudinTolmetin may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tolmetin.Approved, Investigational
DextranTolmetin may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Tolmetin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Tolmetin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Tolmetin may increase the anticoagulant activities of Dextran 75.Approved
DibekacinTolmetin may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Tolmetin is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tolmetin.Approved, Vet Approved
DicoumarolTolmetin may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Tolmetin is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tolmetin.Approved
DihydrostreptomycinTolmetin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tolmetin.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tolmetin.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tolmetin.Approved
DoxorubicinTolmetin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneTolmetin may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Tolmetin is combined with E-6201.Investigational
Edetic AcidTolmetin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTolmetin may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Tolmetin is combined with Enalaprilat.Approved
EnoxacinTolmetin may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinTolmetin may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Tolmetin.Experimental
EpanololTolmetin may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Tolmetin is combined with Epirizole.Approved
EpirubicinTolmetin may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tolmetin.Experimental
EplerenoneTolmetin may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tolmetin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolmetin.Approved
EquileninThe risk or severity of adverse effects can be increased when Tolmetin is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Equilin.Approved
EsmololTolmetin may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tolmetin.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tolmetin.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ethenzamide.Experimental
Ethyl biscoumacetateTolmetin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Tolmetin is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tolmetin.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Feprazone.Experimental
Ferulic acidTolmetin may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tolmetin.Approved, Investigational
FleroxacinTolmetin may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tolmetin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fludrocortisone.Approved, Investigational
FluindioneTolmetin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineTolmetin may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tolmetin.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tolmetin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tolmetin.Approved, Nutraceutical, Vet Approved
FondaparinuxTolmetin may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumTolmetin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tolmetin.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fosinopril.Approved
FramycetinTolmetin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tolmetin.Approved, Vet Approved
GabexateTolmetin may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTolmetin may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTolmetin may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tolmetin.Approved, Withdrawn
GemifloxacinTolmetin may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTolmetin may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTolmetin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATolmetin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Tolmetin may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinTolmetin may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Tolmetin is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Tolmetin is combined with HE3286.Investigational
HeparinTolmetin may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Higenamine.Investigational
HydralazineTolmetin may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tolmetin.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tolmetin.Approved, Investigational
Hygromycin BTolmetin may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Tolmetin is combined with Icatibant.Approved, Investigational
IdarubicinTolmetin may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxTolmetin may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tolmetin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tolmetin.Approved
IndenololTolmetin may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tolmetin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolmetin.Approved, Investigational
IsepamicinTolmetin may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Tolmetin is combined with Istaroxime.Investigational
KanamycinTolmetin may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tolmetin.Approved
LabetalolTolmetin may decrease the antihypertensive activities of Labetalol.Approved
LandiololTolmetin may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tolmetin.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Tolmetin.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Leflunomide.Approved, Investigational
LepirudinTolmetin may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanTolmetin may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololTolmetin may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTolmetin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Tolmetin.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Tolmetin.Approved
LonazolacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tolmetin.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tolmetin.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tolmetin.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tolmetin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Tolmetin is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mefenamic acid.Approved
MelagatranTolmetin may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Meloxicam.Approved, Vet Approved
MepindololTolmetin may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineTolmetin may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Tolmetin is combined with Metamizole.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tolmetin.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolmetin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Methylprednisolone.Approved, Vet Approved
MetipranololTolmetin may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tolmetin.Approved
MetoprololTolmetin may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTolmetin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinTolmetin may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tolmetin.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tolmetin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tolmetin.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nabumetone.Approved
NadololTolmetin may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTolmetin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatTolmetin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Naftifine.Approved
Nalidixic AcidTolmetin may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Tolmetin is combined with NCX 1022.Investigational
NeamineTolmetin may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololTolmetin may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinTolmetin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTolmetin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tolmetin.Approved, Investigational
NetilmicinTolmetin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nitroaspirin.Investigational
NorfloxacinTolmetin may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tolmetin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Olopatadine.Approved
OlsalazineTolmetin may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Tolmetin is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Tolmetin is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Orgotein.Vet Approved
OtamixabanTolmetin may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oxaprozin.Approved
Oxolinic acidTolmetin may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTolmetin may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oxyphenbutazone.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Parecoxib.Approved
ParomomycinTolmetin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Parthenolide.Approved, Investigational
PazufloxacinTolmetin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTolmetin may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTolmetin may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateTolmetin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateTolmetin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Perindopril.Approved
PhenindioneTolmetin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonTolmetin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tolmetin.Approved, Investigational
PindololTolmetin may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidTolmetin may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinTolmetin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tolmetin.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pirfenidone.Approved, Investigational
Piromidic acidTolmetin may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorTolmetin may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinTolmetin may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinTolmetin may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tolmetin.Approved
PractololTolmetin may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tolmetin.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Tolmetin can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Propacetamol.Approved, Investigational
PropranololTolmetin may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tolmetin.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tolmetin.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tolmetin.Vet Approved
Protein CTolmetin may increase the anticoagulant activities of Protein C.Approved
Protein S humanTolmetin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTolmetin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTolmetin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Tolmetin is combined with PTC299.Investigational
PuromycinTolmetin may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tolmetin.Approved
RamiprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinTolmetin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinTolmetin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Risedronate.Approved, Investigational
RivaroxabanTolmetin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinTolmetin may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinTolmetin may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinTolmetin may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tolmetin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tolmetin.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tolmetin.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Tolmetin.Approved, Investigational
SemapimodThe risk or severity of adverse effects can be increased when Tolmetin is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Tolmetin is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Tolmetin is combined with Serrapeptase.Investigational
SisomicinTolmetin may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinTolmetin may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Tolmetin.Approved
SotalolTolmetin may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTolmetin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTolmetin may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinTolmetin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Spirapril.Approved
SpironolactoneTolmetin may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Tolmetin is combined with SRT501.Investigational
StreptomycinTolmetin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTolmetin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Sulindac.Approved, Investigational
SulodexideTolmetin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tolmetin.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Suxibuzone.Experimental
TacrolimusTolmetin may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tolmetin.Approved
TalinololTolmetin may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tolmetin.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tolmetin.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolmetin.Approved, Investigational
TemafloxacinTolmetin may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tolmetin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Teriflunomide.Approved
TertatololTolmetin may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTolmetin may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tixocortol.Approved, Withdrawn
TobramycinTolmetin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tolfenamic Acid.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tolmetin.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tolmetin.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tolmetin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTolmetin may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tolmetin.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Triptolide.Investigational
TrovafloxacinTolmetin may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinTolmetin may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tolmetin.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValrubicinTolmetin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolmetin.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tolmetin.Approved
WarfarinTolmetin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTolmetin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinTolmetin may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinTolmetin may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014643
KEGG Compound
C07149
PubChem Compound
5509
PubChem Substance
46507060
ChemSpider
5308
BindingDB
50295287
ChEBI
71941
ChEMBL
CHEMBL1020
Therapeutic Targets Database
DAP000777
PharmGKB
PA451721
HET
TLT
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Tolmetin
ATC Codes
M01AB03 — TolmetinM02AA21 — Tolmetin
PDB Entries
3s3g
FDA label
Download (77.4 KB)
MSDS
Download (44.3 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Actavis elizabeth llc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
Packagers
  • Amerisource Health Services Corp.
  • DHHS Program Support Center Supply Service Center
  • Dispensing Solutions
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Mylan
  • Novopharm Ltd.
  • Ortho-McNeil-Janssen Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Qualitest
  • Southwood Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • United Research Laboratories Inc.
Dosage forms
FormRouteStrength
CapsuleOral400 mg
TabletOral245 mg
TabletOral600 mg
CapsuleOral400 mg/1
TabletOral200 mg/1
Tablet, film coatedOral600 mg/1
Prices
Unit descriptionCostUnit
Tolectin 600 mg tablet2.43USD tablet
Tolmetin sodium 600 mg tablet2.06USD tablet
Tolmetin Sodium 400 mg capsule1.77USD capsule
Tolmetin sodium 200 mg tablet0.77USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)156 dec °CPhysProp
water solubility222 mg/LNot Available
logP2.79SANGSTER (1993)
pKa3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.131 mg/mLALOGPS
logP2.81ALOGPS
logP2.73ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)3.96ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity72.39 m3·mol-1ChemAxon
Polarizability27.67 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9752
Blood Brain Barrier+0.8387
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.7277
P-glycoprotein inhibitor INon-inhibitor0.9062
P-glycoprotein inhibitor IINon-inhibitor0.9542
Renal organic cation transporterNon-inhibitor0.7999
CYP450 2C9 substrateNon-substrate0.7091
CYP450 2D6 substrateNon-substrate0.7867
CYP450 3A4 substrateNon-substrate0.6233
CYP450 1A2 substrateNon-inhibitor0.9159
CYP450 2C9 inhibitorNon-inhibitor0.9353
CYP450 2D6 inhibitorNon-inhibitor0.9449
CYP450 2C19 inhibitorNon-inhibitor0.9389
CYP450 3A4 inhibitorNon-inhibitor0.9563
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9346
Ames testNon AMES toxic0.8887
CarcinogenicityNon-carcinogens0.8992
BiodegradationReady biodegradable0.5
Rat acute toxicity2.9129 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9535
hERG inhibition (predictor II)Non-inhibitor0.9545
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.07 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0090000000-5053b1021a81c4668b54
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0910000000-7cb6eb9d5a42f35eb4bc
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0900000000-9898c207cc31a596d319
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014l-6900000000-439955132bb3d3d37cf7
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-9200000000-aed48305fd97ea83af6d
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-014i-1900000000-3399455ef4fbd98a64d3

Taxonomy

Description
This compound belongs to the class of organic compounds known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Aryl-phenylketones
Alternative Parents
Benzoyl derivatives / Toluenes / N-methylpyrroles / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides
show 1 more
Substituents
Aryl-phenylketone / Benzoyl / Toluene / Monocyclic benzene moiety / N-methylpyrrole / Substituted pyrrole / Benzenoid / Pyrrole / Heteroaromatic compound / Carboxylic acid derivative
show 10 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid, aromatic ketone, pyrroles (CHEBI:71941)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Burdan F, Szumilo J, Klepacz R, Dudka J, Korobowicz A, Tokarska E, Cendrowska-Pinkosz M, Madej B, Klepacz L: Gastrointestinal and hepatic toxicity of selective and non-selective cyclooxygenase-2 inhibitors in pregnant and non-pregnant rats. Pharmacol Res. 2004 Nov;50(5):533-43. [PubMed:15458776]
  2. Capasso A, Sorrentino L: Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum. Eur J Pharmacol. 1997 Jul 9;330(2-3):199-204. [PubMed:9253954]
  3. Kirkova M, Alexandova A, Kesiova M, Todorov S: In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems. Comparison with non-selective and COX-2 selective NSAIDs. Auton Autacoid Pharmacol. 2007 Apr;27(2):99-104. [PubMed:17391279]
  4. Kennedy JH, Korn N, Thurston RJ: Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility. Reprod Biol Endocrinol. 2003 Oct 9;1:74. [PubMed:14613550]
  5. Capasso A: Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues. Neuropharmacology. 1999 Jun;38(6):871-7. [PubMed:10465690]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Capasso A, Sorrentino L: Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum. Eur J Pharmacol. 1997 Jul 9;330(2-3):199-204. [PubMed:9253954]
  2. Kennedy JH, Korn N, Thurston RJ: Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility. Reprod Biol Endocrinol. 2003 Oct 9;1:74. [PubMed:14613550]
  3. Capasso A: Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues. Neuropharmacology. 1999 Jun;38(6):871-7. [PubMed:10465690]
  4. Burdan F, Szumilo J, Marzec B, Klepacz R, Dudka J: Skeletal developmental effects of selective and nonselective cyclooxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL:(WI)WUBR rats. Toxicology. 2005 Dec 15;216(2-3):204-23. Epub 2005 Sep 22. [PubMed:16182428]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Tryptophan 2,3-dioxygenase activity
Specific Function
Incorporates oxygen into the indole moiety of tryptophan. Has a broad specificity towards tryptamine and derivatives including D- and L-tryptophan, 5-hydroxytryptophan and serotonin (By similarity).
Gene Name
TDO2
Uniprot ID
P48775
Uniprot Name
Tryptophan 2,3-dioxygenase
Molecular Weight
47871.215 Da
References
  1. Dairam A, Antunes EM, Saravanan KS, Daya S: Non-steroidal anti-inflammatory agents, tolmetin and sulindac, inhibit liver tryptophan 2,3-dioxygenase activity and alter brain neurotransmitter levels. Life Sci. 2006 Nov 10;79(24):2269-74. Epub 2006 Aug 1. [PubMed:16952380]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
MPO
Uniprot ID
P05164
Uniprot Name
Myeloperoxidase
Molecular Weight
83867.71 Da
References
  1. Anderson R, Oosthuizen R, Grabow G: Prevention of peroxidase mediated inhibition of neutrophil motility and lymphocyte transformation by levamisole, OMPI, sodium aurothiomalate, indomethacin and tolmetin in vitro. Int J Immunopharmacol. 1981;3(2):123-32. [PubMed:6266970]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Ojingwa JC, Spahn-Langguth H, Benet LZ: Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma. J Pharmacokinet Biopharm. 1994 Feb;22(1):19-40. [PubMed:8027947]
  2. Borga O, Borga B: Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study. J Pharmacokinet Biopharm. 1997 Feb;25(1):63-77. [PubMed:9353694]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]

Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 05:08